公开(公告)号：US20240360457A1

公开(公告)日：2024-10-31

申请号：US18765587

申请日：2024-07-08

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00

CPC classification number: C12N15/1138 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/531

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a cancer cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the cancer cell, the therapeutic compound ultimately being internalized by the cancer cell via endocytosis.

公开(公告)号：US20240150771A1

公开(公告)日：2024-05-09

申请号：US18407815

申请日：2024-01-09

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00

CPC classification number: C12N15/1138 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/531

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.

公开(公告)号：US12006502B2

公开(公告)日：2024-06-11

申请号：US18407815

申请日：2024-01-09

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00 ,  C12Q1/68

CPC classification number: C12N15/1138 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/531

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.

公开(公告)号：US12139713B2

公开(公告)日：2024-11-12

申请号：US18407780

申请日：2024-01-09

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00 ,  C12Q1/68

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.

公开(公告)号：US20240191237A1

公开(公告)日：2024-06-13

申请号：US18407780

申请日：2024-01-09

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00

CPC classification number: C12N15/1138 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/531

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.

公开(公告)号：US20240043846A1

公开(公告)日：2024-02-08

申请号：US18057050

申请日：2022-11-18

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00

CPC classification number: C12N15/1138 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/531

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

公开(公告)号：US20250122508A1

公开(公告)日：2025-04-17

申请号：US18982078

申请日：2024-12-16

Applicant: K2B Therapeutics, Inc. ,  KIST (Korea Institute of Science and Technology)

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a cancer cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the cancer cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis.

公开(公告)号：US20240325550A1

公开(公告)日：2024-10-03

申请号：US18618258

申请日：2024-03-27

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: A61K47/64 ,  A61P35/00 ,  C12N15/113

CPC classification number: A61K47/64 ,  A61P35/00 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/141

Abstract: Therapeutic compounds for inhibiting and reducing the expression of cell surface proteins and methods for treating cancer, inflammation, and diabetes using the therapeutic compounds.

公开(公告)号：WO2023092089A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/080167

申请日：2022-11-18

Applicant: KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY) ,  K2B THERAPEUTICS, INC.

Inventor： KIM, HoWon J. ,  KIM, In-San ,  KIM, Jay S. ,  KIM, Sun Hwa ,  KWON, Ick Chan ,  LEE, Jong Won ,  YANG, Yoo Soo ,  YOON, Hong Yeol

IPC: A61K47/68 ,  A61P35/00

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

公开(公告)号：EP4340893A1

公开(公告)日：2024-03-27

申请号：EP22844608.4

申请日：2022-11-18

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： KIM, HoWon J. ,  KIM, In-San ,  KIM, Jay S. ,  KIM, Sun Hwa ,  KWON, Ick Chan ,  LEE, Jong Won ,  YANG, Yoo Soo ,  YOON, Hong Yeol

IPC: A61K47/68 ,  A61P35/00